Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

April 28, 2020

Study Completion Date

April 28, 2020

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

RO7239361

Take RO7239361 subcutaneously on specified days over a 48 week blinded period

DRUG

Placebo for RO7239361

Take placebo subcutaneously on specified days over a 48 week blinded period

Trial Locations (44)

2145

Children's Hospital Westmead; Paediatrics & Child Health, Westmead

3052

Royal Children's Hospital, Parkville

4101

Lady Cilento Children's Hospital; Neurosciences Department, South Brisbane

9000

UZ Gent, Ghent

20162

Fondazione Serena Onlus - CENTRO CLINICO NEMO, Milano

21205

Kennedy Krieger Institute, Baltimore

30318

Rare Disease Research, LLC, Atlanta

32607

University of Florida, Gainesville

32827

Nemours Children's Hospital, Orlando

41685

Drottning Silvias Barn- och ungdomssjukhus; Kliniken for barnmedicin, Gothenburg

43205

Nationwide Childrens Hospital; Research Institute at Nationwide Childrens Hospital, Columbus

44093

Hotel Dieu; Service Pharmacie Essais Cliniques, Nantes

45122

Universitatsklinikum Essen; Innere Klinik, Essen

45229

Cincinnati Childrens Hospital Medical Center;Investigational Pharmacy, Cincinnati

46026

Hospital Universitari i Politecnic La Fe de Valencia; Servicio de Farmacia, Valencia

52242

University of Iowa, Iowa City

60612

Rush University Medical Center - PPDS, Chicago

63110

Saint Louis Children's Hospital, St Louis

66160

University of Kansas Medical Center, Kansas City

67091

Hopitaux Universitaires de Strasbourg, Strasbourg

69004

Hospices Civils de Lyon, Lyon

75571

Hopital Armand Trousseau; centre reference Maladies Neuro-musculaires Est parisien Neuropediatrie, Paris

85028

Neuromuscular Research Center, Phoenix

89145

Las Vegas Clinic, Las Vegas

94304

Stanford University, Palo Alto

95817

University of California Davis Medical Center, Sacramento

98105

Seattle Children's Hospital, Seattle

98125

Az. Osp. Universitaria Pol. G. Martino; Dip. Neuroscienze, Scienze Psichiatriche e Anest., Messina

06510

Yale University School of Medicine ; Pulmonary & Critical Care, New Haven

01655

University of Massachusetts Memorial Childrens Medical Center; Department of Neurology, Worcester

C1204AAD

Instituto centenario, Buenos Aires

N6A 5W9

London Health Sciences Centre; Children's Hospital; Pediatrics, London

K1H 8L1

Children'S Hospital of Eastern Ontario, Ottawa

00168

Fondazione Policlinico Universitario A Gemelli; Servizio di Farmacia, Rome

663-8501

Hyogo College of Medicine Hospital, Hyōgo

989-3126

Miyagi Children's Hospital, Miyagi

390-8621

Shinshu University Hospital, Nagano

560-8552

National Hospital Organization Osaka Toneyama Medical Center, Osaka

187-8551

National Center of Neurology and Psychiatry, Tokyo

2333 ZA

Leids Universitair Medisch Centrum, Leiden

6525 EX

Radboud University Nijmegen Medical Centre; Ophthalmology, Nijmegen

08950

Hospital Sant Joan De Deu, Esplugues de Llobregas

L12 2AP

Alder Hey Children s Hospital; Department of Pediatrics, Liverpool

WC1N 1EH

UCL Institute of Child Health & Great Ormond Street Hospital for Children, London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03039686 - Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter